Protective antibody levels and dose requirements of IV 5% Nabi hepatitis B immune globulin combined with lamivudine in liver transplantation for hepatitis B induced end stage liver disease: Rolland C Dickson, Mayo Clinic Jacksonville, Jacksonville, FL; Nora Terrault, University of California at San Francisco, San Francisco, CA; Michael B Ishitani, Mayo Clinic Rochester, Rochester, MN; Rajender Reddy, University of Miami, Miami, FL; Patricia Sheiner, Mt Sinai, New York, NY; Velimir Luketic, Medical College of Virginia, Richmond, VA; Terrence Angtuaco, Rush Presbyterian-St Lukes Medical Center, Chicao, IL; Consuelo Soldevilla-Pico, University of Florida, Gainesville, FL; Michael W Fried, University of North Carolina, Chapel Hill, NC; Robert Brown Jr., Columbia Presbyterian Medical Center, New York, NY; Anna S Lok, University of Michigan, Ann Arbor, MI; Janet Johnson, Nabi, Rockville, MD